Wave Life Sciences/WVE

$5.13

6.65%
-
1D1W1MYTD1YMAX

About Wave Life Sciences

Wave Life Sciences Ltd. is a clinical-stage genetic medicines company. The Company is engaged in developing medicines across multiple therapeutic modalities using PRISM, its proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. The Company’s ribonucleic acid (RNA)-targeting oligonucleotides is designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. Its lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (DMD); liver, including alpha-1 antitrypsin deficiency (AATD); and the central nervous system (CNS), including Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These programs include WVE-N531, WVE-006, WVE-003, and WVE-004.

Ticker

WVE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paul Bolno

Employees

250

Headquarters

Null, Singapore

WVE Metrics

BasicAdvanced
$586.88M
Market cap
-
P/E ratio
-$0.86
EPS
-1.17
Beta
-
Dividend rate

What the Analysts think about WVE

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
79.53% upside
High $17.00
Low $5.00
$5.13
Current price
$9.21
Average price target

WVE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
14.63% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$49.2M
40.57%
Net income
$7.2M
-114.85%
Profit margin
14.63%
-110.56%

WVE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 139.25%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.47
-$0.27
-$0.20
$0.07
-
Expected
-$0.41
-$0.04
-$0.33
-$0.18
-$0.23
Surprise
14.63%
575%
-39.66%
-139.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Wave Life Sciences stock

Buy or sell Wave Life Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing